| Preview | Issue Date | Title | Author(s) |
| 2017 | A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis | Ho, P.; Bajel, A.; Burbury, K.; Dunlop, L.; Durrant, S.; Forsyth, C.; Perkins, A.; Ross, D. |
| 2015 | Bi-Nuclear Metal Complexes of 2,6-Bis(1,4,7- triazacyclonon-1-yl-methylene)pyridine with Zinc(II), Copper(II), and Nickel(II) | Coghlan, C.; Campi, E.; Forsyth, C.; Jackson, R.; Hearn, M. |
| 2009 | Bulky triazenide complexes of alumino- and gallohydrides | Alexander, S.; Cole, M.; Forsyth, C.; Furfari, S.; Konstas, K. |
| 2007 | High temperature synthesis of some strontium and barium 2 6-dibenzylphenolates | Cole, M.; Deacon, G.; Forsyth, C.; Junk, P.; Proctor, K.; Scott, J.; Strauss, C. |
| 2014 | Metal complexes of new bis(tacn) ligands: Syntheses and structures of copper(II) complexes | Coghlan, C.; Campi, E.; Forsyth, C.; Roy Jackson, W.; Hearn, M. |
| 2012 | Phosphodiester cleavage properties of copper(II) complexes of 1,4,7-triazacyclononane ligands bearing single alkyl guanidine pendants | Tjioe, L.; Joshi, T.; Forsyth, C.; Moubaraki, B.; Murray, K.; Brugger, J.; Graham, B.; Spiccia, L. |
| 2010 | Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial | Yeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.) |
| 2007 | Steric modulation of coordination number and reactivity in the synthesis of Lanthanoid(III) formamidinates | Cole, M.; Deacon, G.; Forsyth, C.; Junk, P.; Konstas, K.; Wang, J. |
| 2006 | Synthesis and structural characterisation of heavy alkaline earth N,N '-bis( aryl) formamidinate complexes | Cole, M.; Deacon, G.; Forsyth, C.; Konstas, K.; Junk, P. |
| 2008 | The reactivity of N-heterocyclic carbenes and their precursors with [Ru-3(CO)(12)] | Bruce, M.; Cole, M.; Fung, R.; Forsyth, C.; Hilder, M.; Junk, P.; Konstas, K. |
| 2015 | TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets | Yeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Trotman, J.; Forsyth, C.; Taper, J.; Ross, D.; Beresford, J.; Tam, C.; et al. |
| 2020 | Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing loss | Venugopal, P.; Gagliardi, L.; Forsyth, C.; Feng, J.; Phillips, K.; Babic, M.; Poplawski, N.K.; Rienhoff, H.Y.; Schreiber, A.W.; Hahn, C.N.; Brown, A.L.; Scott, H.S. |
| 2012 | When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? | Bird, R.; Kenealy, M.; Forsyth, C.; Wellwood, J.; Leahy, M.; Seymour, J.; To, L. |
